Pharmacogenomics and pharmacogenetics of thiazolidinediones: Role in diabetes and cardiovascular risk factors

Pharmacogenomics

Volumn 15, Issue 16, 2014, Pages 2063-2082

  Della Morte, David ^a,b,c   Palmirotta, Raffaele ^c   Rehni, Ashish K ^b   Pastore, Donatella ^a   Capuani, Barbara ^a   Pacifici, Francesca ^a   De Marchis, Maria Laura ^c   Dave, Kunjan R ^b   Bellia, Alfonso ^a   Fogliame, Giuseppe ^d   Ferroni, Patrizia ^c   Donadel, Giulia ^a   Cacciatore, Francesco ^e   Abete, Pasquale ^f   Dong, Chuanhui ^b   Pileggi, Antonello ^b   Roselli, Mario ^a   Ricordi, Camillo ^b   Sbraccia, Paolo ^a,d   Guadagni, Fiorella ^c   Rundek, Tatjana ^b   Lauro, Davide ^a,d   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e Department of Neurorehabilitation   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cardiovascular disease; diabetes; pharmacogenetics; pharmacogenomics; single nucleotide polymorphisms; thiazolidinediones; vascular risk factors

Indexed keywords

ABC TRANSPORTER A1; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR; BIGUANIDE DERIVATIVE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE TRANSPORTER 4; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 6; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR PAX4; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE;

ADIPOGENESIS; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFORMATIONAL TRANSITION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG FATALITY; DRUG METABOLISM; DRUG WITHDRAWAL; EDEMA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FRACTURE; GENETIC VARIABILITY; GLUCOSE HOMEOSTASIS; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIGAND BINDING; LIPID METABOLISM; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOGENETICS; PHARMACOGENOMICS; PLEIOTROPY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; VASCULAR DISEASE; CARDIOVASCULAR DISEASES; GENETICS; PERSONALIZED MEDICINE;

CARDIOVASCULAR DISEASES; CHROMANS; DIABETES MELLITUS; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84919830319     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.162     Document Type: Review

References (123)

1. Meerza D, Naseem I, Ahmed. J. Pharmacology of signaling pathways: in Type 2 diabetes. Diab. Metabol. Syndr. 7(3), 180-185 (2013
2. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-1118 (2004
3. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-Activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70, 341-367 (2001
4. Martens FM, Visseren FL, Lemay J, De Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62(10), 1463-1480 (2002
5. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics 8(8), 917-931 (2007
6. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Thiazolidinediones and the risk of incident congestive heart failure among patients with Type 2 diabetes mellitus. Pharmacoepidemiol. Drug Saf. 20(8), 785-796 (2011
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007
8. Kumar S, Hoffman SJ, Samadfam R, et al. The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. J. Bone Miner Res. 28(7), 1653-1665 (2013
9. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29(8), 1963-1972 (2006
10. Tolman KG. Thiazolidinedione hepatotoxicity: a class effect?. Int. J. Clin. Pract. Suppl. (113), 29-34 (2000
11. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493), 1279-1289 (2005
12. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-Analysis of randomized trials. JAMA 298(10), 1180-1188 (2007
13. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Diabetologia 56(1), 228-229 (2013
14. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45(12), 1661-1669 (1996
15. Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435 (2002
16. Furuta M, Yano Y, Gabazza EC, et al. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 56(3), 159-171 (2002
17. Armoni M, Kritz N, Harel C, et al. Peroxisome proliferator-Activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J. Biol. Chem. 278(33), 30614-30623 (2003
18. Jiang G, Dallas-Yang Q, Li Z, et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-Term treatment with PPARgamma agonists. Diabetes 51(8), 2412-2419 (2002
19. Leonardini A, Laviola L, Perrini S, Natalicchio A, Giorgino F. Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity. PPAR Res. 2009, 818945 (2009
20. Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S. PPARgamma agonist beyond glucose lowering effect. Korean J. Intern. Med. 26(1), 19-24 (2011
21. Sugawara A, Takeuchi K, Uruno A, et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens. Res. 24(3), 229-233 (2001
22. Uruno A, Matsuda K, Noguchi N, et al. Peroxisome proliferator-Activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J. Mol. Endocrinol. 46(1), 37-49 (2011
23. Ikeda Y, Sugawara A, Taniyama Y, et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-Activated receptor gamma in macrophages via an interaction with NRF2. J. Biol. Chem. 275(42), 33142-33150 (2000
24. Sugawara A, Uruno A, Kudo M, et al. Transcription suppression of thromboxane receptor gene by peroxisome proliferator-Activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J. Biol. Chem. 277(12), 9676-9683 (2002
25. Kudzma DJ. Effects of thiazolidinediones for early treatment of Type 2 diabetes mellitus. Am. J. Manag. Care 8(16 Suppl.), S472-S482 (2002
26. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with Type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin. Ther. 25(Suppl. B), B64-B80 (2003
27. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013, 152786 (2013
28. Jiang DQ, Chu LX, Liu ZY, Zhang SB. Pioglitazone decreased CD40/CD40L expression on human umbilical vein endothelial cells induced by oxidized low-density lipoprotein. Clin. Chim. Acta 370(1-2), 94-99 (2006
29. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front. Biosci. 13, 1813-1826 (2008
30. Tureyen K, Kapadia R, Bowen KK, et al. Peroxisome proliferator-Activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. NeuroChem. 101(1), 41-56 (2007
31. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-Activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest. 83(12), 1715-1721 (2003
32. Finegood DT, Mcarthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50(5), 1021-1029 (2001
33. Wang X, Liu X, Zhan Y, et al. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-Activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation. J. Pharmacol. Exp. Ther. 334(3), 820-829 (2010
34. Wang X. Assessment of cardiac safety for PPARgamma agonists in rodent models of heart failure: a translational medicine perspective. Curr. Mol. Pharmacol. 5(2), 264-271 (2012
35. Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot. Essent. Fatty Acids 73(1), 65-75 (2005
36. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26(5), 244-251 (2005
37. Liu HL, Lin YG, Wu J, et al. Impact of genetic polymorphisms of leptin and TNF-Alpha on rosiglitazone response in Chinese patients with Type 2 diabetes. Eur. J. Clin. Pharmacol. 64(7), 663-671 (2008
38. Pan HJ, Reifsnyder P, Vance DE, Xiao Q, Leiter EH. Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of Type 2 diabetes. Diabetes 54(6), 1854-1862 (2005
39. Pan HJ, Lin Y, Chen YE, Vance DE, Leiter EH. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of Type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vasc. Pharmacol. 45(1), 65-71 (2006
40. Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, Mistry J. Differential endocrine responses to rosiglitazone therapy in new mouse models of Type 2 diabetes. Endocrinology 147(2), 919-926 (2006
41. Kirchheiner J, Meineke I, Fuhr U, Rodriguez-Antona C, Lebedeva E, Brockmoller J. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 9(3), 277-288 (2008
42. Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80(6), 657-667 (2006
43. Li Z, Peng X, Wu Y, Xia Y, Liu X, Zhang Q. The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with Type 2 diabetes. Diabetes Obes. Metab. 10(9), 794-802 (2008
44. Ren W, Zhang SH, Wu J, Ni YX. Polymorphism of the leptin gene promoter in pedigrees of Type 2 diabetes mellitus in Chongqing, China. Chin. Med. J. (Engl.) 117(4), 558-561 (2004
45. Sookoian SC, Gonzalez C, Pirola CJ. Meta-Analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes. Res. 13(12), 2122-2131 (2005
46. Seda O, Sedova L, Oliyarnyk O, et al. Pharmacogenomics of metabolic effects of rosiglitazone. Pharmacogenomics 9(2), 141-155 (2008
47. Yu W, Hu C, Zhang R, et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with Type 2 diabetes. Clin. Pharmacol. Ther. 89(3), 437-442 (2011
48. Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with Type 2 diabetes. Diabetes Care 28(5), 1139-1144 (2005
49. Kang ES, Cha BS, Kim HJ, et al. The 11482G A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in Type 2 diabetes. Diabetes Care 29(6), 1320-1324 (2006
50. Yang M, Huang Q, Wu J, et al. Effects of UCP2-866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes. Br. J. Clin. Pharmacol. 68(1), 14-22 (2009
51. Jazet IM, Pijl H, Meinders AE. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth. J. Med. 61(6), 194-212 (2003
52. Chen M, Hu C, Zhang R, et al. Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese Type 2 diabetes patients. Pharmacogenomics J. 14(5), 488-492 (2014
53. Wang J, Bao YQ, Hu C, et al. Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed Type 2 diabetes patients. Acta Pharmacol. Sin. 29(2), 252-258 (2008
54. Krempler F, Esterbauer H, Weitgasser R, et al. A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces Type 2 diabetes risk in obese middle-Aged humans. Diabetes 51(11), 3331-3335 (2002
55. Zhang KH, Huang Q, Dai XP, et al. Effects of the peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with Type 2 diabetes mellitus. J. Clin. Pharmacol. 50(9), 1022-1030 (2010
56. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin. Invest. 114(9), 1281-1289 (2004
57. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27(2), 484-490 (2004
58. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin. Drug Saf. 11(4), 565-579 (2012
59. Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res. Clin. Pract. 98(2), 175-186 (2012
60. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int. J. Clin. Pract. Suppl. (121), 19-25 (2001
61. Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin. Pharmacokinet. 46(1), 1-12 (2007
62. Aquilante CL, Kosmiski LA, Bourne DW, et al. Impact of the CYP2C8 3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br. J. Clin. Pharmacol. 75(1), 217-226 (2013
63. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8 3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos. 36(1), 73-80 (2008
64. Kadam R, Bourne D, Kompella U, Aquilante C. Effect of cytochrome P450 2C8 3 on the population pharmacokinetics of pioglitazone in healthy Caucasian volunteers. Biol. Pharm. Bull. 36(2), 245-251 (2013
65. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 42(9), 1033-1049 (1999
66. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-To-Alanine substitution at codon 12 of peroxisome proliferator-Activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. BioChem. Biophys. Res. Commun. 268(1), 178-182 (2000
67. Ramirez-Salazar M, Perez-Luque E, Fajardo-Araujo M, Garza SM, Malacara JM. Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women. Menopause 15(6), 1151-1156 (2008
68. Hsieh MC, Lin KD, Tien KJ, et al. Common polymorphisms of the peroxisome proliferator-Activated receptor-gamma (Pro12Ala) and peroxisome proliferator-Activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with Type 2 diabetes mellitus. Metabolism 59(8), 1139-1144 (2010
69. Pei Q, Huang Q, Yang GP, et al. PPAR-gamma2 and PTPRD gene polymorphisms influence Type 2 diabetes patients response to pioglitazone in China. Acta Pharmacol. Sin. 34(2), 255-261 (2013
70. Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH. Polymorphism of peroxisome. proliferator-Activated receptor gamma (PPARgamma) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in Type 2 diabetes. Eur. J. Pharmacol. 671(1-3), 1-6 (2011
71. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 409(6818), 307-312 (2001
72. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 303(5661), 1195-1198 (2004
73. Rangwala SM, Rich AS, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53(8), 1937-1941 (2004
74. Makino H, Shimizu I, Murao S, et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at-420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in Type 2 diabetes. Endocr. J. 56(9), 1049-1058 (2009
75. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 296(21), 2572-2581 (2006
76. Honda T, Kaikita K, Tsujita K, et al. Pioglitazone, a peroxisome proliferator-Activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J. Mol. Cell Cardiol. 44(5), 915-926 (2008
77. Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am. J. Physiol. Heart Circ. Physiol. 295(6), H2436-H2446 (2008
78. Wang H, Zhu QW, Ye P, et al. Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. BioSci. Trends 6(6), 325-332 (2012
79. Saitou M, Osonoi T, Kawamori R, et al. Genetic risk factors and the anti-Atherosclerotic effect of pioglitazone on carotid atherosclerosis of subjects with Type 2 diabetes a retrospective study. J. Atheroscler. Thromb. 17(4), 386-394 (2010
80. Groenemeijer BE, Hallman MD, Reymer PW, et al. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation 95(12), 2628-2635 (1997
81. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-Activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27(7), 1660-1667 (2004
82. Wang G, Wang X, Zhang Q, Ma Z. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with Type 2 diabetes mellitus. Int. J. Clin. Pract. 61(4), 552-557 (2007
83. Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab. Pharmacokinet. 26(1), 60-70 (2011
84. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338(13), 916-917 (1998
85. He K, Talaat RE, Pool WF, et al. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32(6), 639-646 (2004
86. Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-Associated hepatotoxicity in Japanese patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73(5), 435-455 (2003
87. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-Transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. BioChem. J. 300(Pt 1), 271-276 (1994
88. Rebbeck TR. Molecular epidemiology of the human glutathione S-Transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6(9), 733-743 (1997
89. Oniki K, Ueda K, Hori M, Mihara S, Marubayashi T, Nakagawa K. Glutathione-S-Transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes as a risk factor for alcoholic mild liver dysfunction. Clin. Pharmacol. Ther. 81(5), 634-635 (2007
90. Kumashiro R, Kubota T, Koga Y, et al. Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene. Hepatol. Res. 26(4), 337-342 (2003
91. Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-Activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 27(6), 1365-1368 (2004
92. Wolford JK, Yeatts KA, Dhanjal SK, et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54(11), 3319-3325 (2005
93. Florez JC, Jablonski KA, Sun MW, et al. Effects of the Type 2 diabetes-Associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J. Clin. Endocrinol. Metab. 92(4), 1502-1509 (2007
94. Distefano JK, Watanabe RM. Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals (Basel) 3(8), 2610-2646 (2010
95. Franks PW, Jablonski KA, Delahanty L, et al. The Pro12Ala variant at the peroxisome proliferator-Activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 50(12), 2451-2460 (2007
96. Moore AF, Jablonski KA, Mcateer JB, et al. Extension of Type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57(9), 2503-2510 (2008
97. Majithia AR, Jablonski KA, Mcateer JB, et al. Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. Diabetologia 54(10), 2570-2574 (2011
98. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with Type 2 diabetes. Clin. Ther. 27(8), 1181-1195 (2005
99. Cox SL. Muraglitazar: an agent for the treatment of Type 2 diabetes and associated dyslipidemia. Drugs Today 41(9), 579-587 (2005
100. Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-Activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29(5), 1016-1023 (2006
101. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294(20), 2581-2586 (2005
102. Geese WJ, Achanzar W, Rubin C, et al. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-Activated receptor gamma agonists. Pharmacogenet. Genomics 18(10), 903-910 (2008
103. Panicker GK, Karnad DR, Salvi V, Kothari S. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J. Assoc. Phys. India 60, 56-61 (2012
104. Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13(12), 715-720 (2003
105. Visser LE, Van Schaik RH, Jan Danser AH, et al. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet. Genomics 17(7), 473-479 (2007
106. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285(5431), 1276-1279 (1999
107. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch. Biochem. Biophys. 433(2), 413-420 (2005
108. Sahi J, Black CB, Hamilton GA, et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos. 31(4), 439-446 (2003
109. Avandia. www.avandia.com
110. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (3), CD006063 (2007
111. Graham DJ, Ouellet-Hellstrom R, Macurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4), 411-418 (2010
112. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for Type 2 diabetes mellitus. Cochrane Database Syst Rev. (4), CD006060 (2006
113. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-Analysis of randomized clinical trials. Diabetes Obes. Metab. 10(12), 1221-1238 (2008
114. Ruano G, Bernene J, Windemuth A, et al. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin. Chim. Acta 400(1-2), 48-55 (2009
115. Cho S, Atwood JE. Peripheral edema. Am. J. Med. 113(7), 580-586 (2002
116. Bailey SD, Xie C, Do R, et al. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care 33(10), 2250-2253 (2010
117. Chang TJ, Liu PH, Liang YC, et al. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with Type 2 diabetes. Pharmacogenet. Genomics 21(12), 829-836 (2011
118. Hansen L, Ekstrom CT, Tabanera YPR, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-Activated receptor-gamma/alpha agonist-induced edema in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 91(9), 3446-3450 (2006
119. Kawaguchi-Suzuki M, Frye RF. Current clinical evidence on pioglitazone pharmacogenomics. Front. Pharmacol. 4, 147 (2013
120. Wilson PW, Dagostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162(16), 1867-1872 (2002
121. Masud S, Ye S, Group SaS. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-Analysis. J. Med. Genet. 40(10), 773-780 (2003
122. Gurnell M. Striking the right balance in targeting PPARgamma in the metabolic syndrome: novel insights from human genetic studies. PPAR Res. 2007, 83593 (2007
123. Franks PW, Jablonski KA, Delahanty LM, et al. Assessing gene-Treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia 51(12), 2214-2223 (2008